ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Kris Discusses the Pemetrexed Trial Results

Mark G. Kris, MD
Published: Thursday, Jun 23, 2011

Mark G. Kris, MD, the chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the pemetrexed clinical trial results.

Dr. Kris says by continuing pemetrexed in patients who began their treatments with pemetrexed, the patients had a longer disease-free survival. Generally disease-free survival translates into life where cancer does not disrupt it. That improvement was achieved just by continuing a medicine that the patients were already on. Survival data is not out yet, and it's something that will be looked for, but regardless, the time free of cancer is clearly improved.
Mark G. Kris, MD, the chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the pemetrexed clinical trial results.

Dr. Kris says by continuing pemetrexed in patients who began their treatments with pemetrexed, the patients had a longer disease-free survival. Generally disease-free survival translates into life where cancer does not disrupt it. That improvement was achieved just by continuing a medicine that the patients were already on. Survival data is not out yet, and it's something that will be looked for, but regardless, the time free of cancer is clearly improved.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x